Atlas Trials

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

Clinical trial NCT06375512 · COMPLETED

Trial details

NCT number
NCT06375512
Sponsor
Shenzhen Shenxin Biotechnology Co., Ltd
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Herpes Zoster
Start date
2024-07-05
Primary completion
2026-02-20
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.